Stocks in Hong Kong fluctuate | Xinda Biotech (01801.HK) rises nearly 3%, announces the completion of the first dose administration to subjects in the phase III clinical study of Marcydupeptide (GLORY-3) on related obesity.
According to the Securities Times app, Sinda Bio (01801.HK) surged by nearly 3%. As of the time of writing, the stock was up by 2.3% at 51.15 Hong Kong dollars with a trading volume of 170 million Hong Kong dollars.
Latest
9 m ago
